An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects greater than or Equal to 1 and Less Than or Equal to 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.

Trial Profile

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects greater than or Equal to 1 and Less Than or Equal to 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Daratumumab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Vincristine
  • Indications Acute lymphoblastic leukaemia; Lymphoma
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Jan 2018 Planned End Date changed from 17 Jun 2021 to 9 Aug 2021.
    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top